Neurodegenerative disease Archives

More News! 17 Jul 2024

Is tau protein the key to defeating Alzheimer’s? Asceneuron thinks so and raises $100 million to prove it

Discover yet another exciting deal in biotech with Asceneuron raising $100 million to advance its Alzheimer’s candidate, ASN51.

July 17, 2024 - 10 minutesmins - By Jules Adam

In Depth 4 Jul 2024

Parkinson’s disease: biotech’s pursuit for more therapies

Rigorous research aims to boost therapeutic options for people with Parkinson’s disease. What do biotechs have in store?

July 4, 2024 - 10 minutesmins - By Roohi Mariam Peter

Best in Biotech 30 May 2024

Stem cell therapy’s avant-garde: Eight companies leading the way

Stem cell therapy has gained traction over the recent years and the market is growing, discover eight companies advancing the field.

May 30, 2024 - 11 minutesmins - By Jules Adam

alchemyrefiner alchemymagic 1 37c41ba7 555f 4f93 ad44 39b31d752775 0

Podcast 15 Mar 2024

Reformulating psychedelics for neurodegenerative diseases

Discover how Terran Biosciences is at the forefront of revolutionizing neurological care through innovative psychedelics treatments.

March 15, 2024

In Depth 4 Mar 2024

ALS: how close are we to a cure?

Let us take a look at how the hunt for amyotrophic lateral sclerosis (ALS) drugs has advanced over the past few years.

March 4, 2024 - 9 minutesmins - By Roohi Mariam Peter

In Depth 19 Jan 2024

Re-coding the brain: Is CRISPR capable of curing neurodegenerative diseases?

Check out our latest article as we explore some of the latest research around using CRISPR technology to treat neurodegenerative diseases.

January 19, 2024 - 9 minutesmins - By Willow Shah-Neville

Podcast 12 Jan 2024

Could natural killer cells transform Alzheimer’s treatment?

Join Dr. Paul Song, CEO of NKGen Biotech, in a podcast exploring the revolutionary use of NK cells for Alzheimer’s treatment.

January 12, 2024

In Depth 9 Nov 2023

Blood tests for Alzheimer’s: a hit or a miss?

Doctor’s typically diagnose Alzheimer’s with the help of brain imaging and cognitive tests, along with taking a patient’s medical history into account. But lately, blood tests are gaining recognition for its ability to rule out other potential causes of memory loss, and to diagnose Alzheimer’s more quickly. With American healthcare company Labcorp launching its trio […]

November 9, 2023 - 10 minutesmins - By Roohi Mariam Peter

In Depth 26 Oct 2023

Behind closed doors: The unseen controversies and scandals in Alzheimer’s drug trials

Alzheimer’s disease is the most common form of dementia – which currently affects more than 55 million people globally – making up 60% to 70% of cases. It is a complex disease, encompassing multiple interrelated and progressive destructive processes in the brain, resulting in neuron damage that extends to parts of the brain that enable […]

October 26, 2023 - 11 minutesmins - By Willow Shah-Neville

News and Trends 13 Jul 2023

Partnership to progress neurodegenerative disorder treatments

IRBM, Rainwater Charitable Foundation (RCF, Fort Worth, Texas), a private family foundation, and Weill Cornell Medicine (based in New York) are starting a multi-year drug discovery collaboration to identify small molecule cGAS (cyclic GMP-AMP synthase) inhibitors for the treatment of tauopathies and other neurodegenerative diseases. The collaboration brings together IRBM’s capabilities in drug discovery and […]

July 13, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 8 Jun 2023

Minoryx can start phase 3 trial for cerebral adrenoleukodystrophy patients

Spanish-headquartered Minoryx Therapeutics says the U.S. Food and Drug Administration (FDA) has approved its phase 3 clinical trial (CALYX) of lead candidate leriglitazone, to treat adult male X-linked adrenoleukodystrophy (X-ALD) patients with cerebral adrenoleukodystrophy (cALD). X-ALD is an orphan neurodegenerative disease. The global incidence of X-ALD is approximately six to eight per 100,000 live births. […]

June 8, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 27 Apr 2023

Biogen ALS drug gets FDA ok

The U.S. Food and Drug Administration (FDA) has approved Biogen’s QALSODY (tofersen) 100 mg/15mL injection for the treatment of amyotrophic lateral sclerosis (ALS) in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene. This indication is approved under accelerated approval based on reduction in plasma neurofilament light chain (NfL) observed in patients […]

April 27, 2023 - 5 minutesmins - By Jim Cornall

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Neurodegenerative disease

Is tau protein the key to defeating Alzheimer’s? Asceneuron thinks so and raises $100 million to prove it

Parkinson’s disease: biotech’s pursuit for more therapies

Stem cell therapy’s avant-garde: Eight companies leading the way

Reformulating psychedelics for neurodegenerative diseases

ALS: how close are we to a cure?

Re-coding the brain: Is CRISPR capable of curing neurodegenerative diseases?

Could natural killer cells transform Alzheimer’s treatment?

Blood tests for Alzheimer’s: a hit or a miss?

Behind closed doors: The unseen controversies and scandals in Alzheimer’s drug trials

Partnership to progress neurodegenerative disorder treatments

Minoryx can start phase 3 trial for cerebral adrenoleukodystrophy patients

Biogen ALS drug gets FDA ok

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!